A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was 'In patients coming to theatre with an intra aortic balloon pump (IABP), is it better to turn it off or keep it on while on bypass?' Altogether 46 papers were found using the reported search, of which 11 represented the best evidence to answer the clinical question. Nine of them were randomised controlled trials (RCTs). The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. The different RCTs were performed looking at various effects of IABP induced pulsatility during cardiopulmonary bypass (CPB) and cardioplegic arrest. These studies showed that IABP induced pulsatile perfusion results in improved perfusion to vital organs, better lung function in chronic obstructive pulmonary disease patients, ameliorates the coagulative system and lowers endothelial activation. Despite these facts a survey in the UK and Ireland showed that 80.5% of cardiac surgeons stop IABP on commencing CPB. We conclude that in patients who already have IABP in-situ whilst going on CPB there is enough evidence in the literature to suggest that it should be turned on to internal trigger mode. Although several randomised control trials in this field have conveyed considerable benefit in terms of biochemical markers measured, none of them have resulted in better clinical outcomes in terms of reduction in major morbidity or mortality. This may be largely due to the small sample size in most of these studies. Seven out of 11 papers were published by same group of authors.
Introduction
A best evidence topic was constructed according to a structured protocol. This is fully described in ICVTS w1x.
Three-part question
In wpatients with intra aortic balloon pumpx undergoing wcardiopulmonary bypassx should the IABP be turned on wopposed to common practice to turn offx?
Clinical scenario
You move to a cardiothoracic unit in another hospital as a part of your rotation. During the first week with the consultant you operate on a patient who is on an intra aortic balloon pump (IABP). The consultant requests the perfusionist to keep IABP on at 80 bpm in internal trigger mode in contrast to what you have seen with your previous consultant who used to turn it off. When asked about it he tells you that IABP gives pulsatile flow during cardiopulmonary bypass (CPB) which results in improved perfusion *Corresponding author. Tel.: q44 7946 248682; fax: q44 1752 763830. E-mail address: sharathhosmane@gmail.com (S.R. Hosmane).
to vital organs in the body. With these reasons in mind, you resort to confirming this through the literature.
Search strategy
Medline 1950-January 2010 using healthcare databases advanced search via health information resources (www.library.nhs.uk). w(cardioplegic arrest) OR (cardiopulmonary bypass)x.ti,ab AND w(balloon*) OR (counterpulsation)x.ti,ab AND (pulsatil*).ti,ab.
Search outcome
Forty-six papers were found using the reported search. From these 11 papers were identified that provided the best evidence to answer the question. These are tabulated in Table 1 .
Comments
The first study in this area was done by Pappas et al. w2x , who published their study in 1975. They selected 56 patients who needed IABP and used it to produce pulsatile flow during CPB and compared them with controls. They measured biochemical markers of myocardial metabolic S.R. Hosmane, A.G. Dawson / Interactive CardioVascular and Thoracic Surgery 11 (2010) IABP, intra aortic balloon pump; CPB, cardiopulmonary bypass; NS, not significant; COPD, chronic obstructive pulmonary disease; CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; aPTT, activated partial thromboplastin time; ATIII, Antithrombin III; MCP-I, monocyte chemotactic protein-I; VEGF, vascular endothelial growth factor; ICU, intensive care unit. function and over all body tissue injury. Their results showed statistically significant results supporting the use of IABP. Kawahara et al. w3x , performed a randomised controlled trial (RCT) to study the effect of IABP induced pulsatile perfusion on cerebral oxygenation during normothermic Downloaded from https://academic.oup.com/icvts/article-abstract/11/3/314/814689 by guest on 09 March 2019 CPB. They recruited 22 patients and randomly divided them into Group 1 (non-pulsatile) and Group 2 (pulsatile). The key measurements were regional cerebral oxygenation using spectrophotometric probe and right jugular venous oxygen saturations. Their results did not show any significant differences between the two groups.
Hashimoto et al. w4x, performed a similar but non-randomised study in 2001. They had two groups -normothermic (368C) and hypothermic (308C) CPB. Furthermore they divided each group into pulsatile (IABP) and non-pulsatile. In addition, they had another set of patients in a normothermic group with increased CPB flow at 2.8 l as opposed to 2.5 l in the rest of the patients. They studied cerebral oxygenation both during normothermic and hypothermic CPB. Their results correlated with Kawahara et al. w3x findings in the normothermic group but they showed statistically significant benefits during hypothermic (308C) CPB.
Onorati et al. published their first RCT in 2005 looking at splanchnic function during pulsatile CPB w6x. Forty patients recruited between January 2004 and November 2004 were randomly assigned into Group A (non-pulsatile) and Group B (pulsatile). Biochemical markers measured for renal, hepatic and pancreatic functions were significantly better in Group B. But these results did not make any difference to the intensive care unit (ICU) stay and hospital outcomes of the patients in the two groups. The second RCT in 2006 was aimed at the effect of IABP induced pulsatile CPB on lung function in patients with history of chronic obstructive pulmonary disease (COPD) w7x. They recruited 50 patients between January 2004 and July 2005 with COPD and requiring preoperative IABP and randomly divided them into Group A (IABP off during CPB) and Group B (IABP on during CPB). Although this study showed that the lung function was preserved in COPD patients with pulsatile CPB the length of ICU stay and hospital outcomes were comparable between the two groups. Another RCT in August 2007 w8x recruited 100 patients (64 patients with eGFR G60 mly miny1.73 m and 36 patients with eGFR 30-59 mlyminy1.73 2 m ) and randomly divided them into Group A (IABP off) and 2 Group B (IABP on). No differences were noted between the two groups for daily diuresis. The renal function (measured as eGFR) during myocardial reperfusion was significantly better in Group B compared to Group A (P-0.001). In June 2008, a RCT of 96 patients w9x divided into pulsatile (Group A) and non-pulsatile (Group B) CPB was published. This study was aimed at the benefits of using IABP during CPB on the coagulation system. Group A patients showed significantly lower chest drainage, transfusion requirement and increased haematocrit, platelets and fibrinogen compared to Group B. They concluded that IABP induced pulsatile CPB ameliorates coagulative system activation following CPB. In another RCT w10x, they looked at whole body perfusion in two groups (pulsatile and non-pulsatile). One hundred and fifty-eight patients undergoing coronary artery bypass grafting (CABG) were recruited for this study. The variables measured included haemodynamic response (mean arterial pressure and indexed systemic vascular resistance), biochemical markers for renal and liver function. Their results demonstrated that IABP induced pulsatile flow during CPB improves the whole body perfusion. A similar RCT in the elderly ()70 years of age) w11x showed comparable results. The most recent RCT published in June 2009 w12x randomised 40 patients between September 2007 and February 2008 into two groups -Group A (pulsatile) and Group B (non-pulsatile). Inflammatoryyendothelial response was measured by pro-inflammatory, anti-inflammatory cytokines and endothelial markers. They concluded that IABP-induced pulsatile perfusion allows lower endothelial activation during CPB and higher anti-inflammatory cytokines secretion.
As shown by the above studies the IABP induced pulsatile flow during CPB confers significant benefits in terms of perfusion to the vital organs. There were no benefits shown by these studies on major morbidity and mortality but this can be attributed largely to the small sample sizes in most of these trials. Despite these facts a survey done by Mulay et al. w13x in the UK and Ireland showed that 80.5% of cardiac surgeons stop IABP on commencing CPB.
Clinical bottom line
In patients having preoperative IABP undergoing CPB there is enough evidence in the literature to support that IABP turned to internal trigger mode of 80 bpm confers beneficial effects by increasing perfusion to vital organs through pulsatile flow. There is no evidence of its harmful effects.
